ImmuneBridge is a startup based in the United States, most recent round Series A, 2 tracked investors.
ImmuneBridge is a company headquartered in the United States. Its most recent tracked round is Series A. Brouky records 2 investors associated with the company.
ImmuneBridge develops allogeneic cellular immunotherapies using a proprietary stem cell expansion technology to create scalable, high-quality immune cell therapies for cancer and other diseases.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.